What is Orca Bio's FDA approved Tregzi cell therapy for blood cancer?

Orca Bio’s Tregzi is the first FDA‑approved allogeneic regulatory T cell therapy for blood cancer patients needing transplants. The approval moves the company into commercial operations and introduces a new approach using regulatory T cells instead of engineered cytotoxic ones, potentially reshaping transplant immunology and post‑transplant care.